Last reviewed · How we verify
NCT04830683: ENDOCOVID
Endothelial Dysfunction in Covid-19
trial in Covid19 in 85 participants. Status unknown.
25 March 2021
Quick facts
| Lead sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 85 |
| Start date | 27 April 2020 |
| Primary completion | 25 March 2021 |
| Estimated completion | 1 April 2021 |
| Sites | 1 location across Belgium |
Conditions studied
- Covid19 — all drugs for Covid19 →
- Hypoxemic Respiratory Failure — all drugs for Hypoxemic Respiratory Failure →
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain — full company profile →
Who can join
Adults 18 to 75, any sex, with Covid19 or Hypoxemic Respiratory Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
SARS-CoV-2 targets endothelial cells via the angiotensin-converting enzyme 2 receptor. The specific impact of the resulting endothelial injury is currently unknown but may contribute to the pro-coagulant state classically described during Covid-19 disease and commonly associated with an exacerbated activation of the renin-angiotensin-aldosterone system.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04830683
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Cliniques universitaires Saint-Luc- Université Catholique de Louvain trials
Trials by the same sponsor.
- NCT07464938 — New Tools and Predictive Markers in the Prognosis of Hypoxic-ischemic Encephalopathy Following Cardiac Arrest · NA · recruiting
- NCT07173036 — Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification Accordin · NA · not yet recruiting
- NCT07245745 — Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer · NA · recruiting
- NCT07588490 — Treatment of Acute Low Back Pain With Transcutaneous Electrical Neurostimulation in Emergency Departments · NA · recruiting
- NCT07161219 — Implementation of New Exercise Protocols in Cardiac Rehabilitation. · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04830683 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Last refreshed: 9 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04830683.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing